Tel Hashomer Medical Research Infrastructure and Services Ltd.

Ramot University Authority for Applied Research and Industrial Development Limited

Joab Chapman

Efrat Shavit-Stein

Michael Jay Brownstein

Yoel Kloog

Efrat Shavit-stein

Efrat Shavit Stein

Rafael Bruck

David Orion

Dimitrius Karussis

Zeev Itsekson-Hayosh

Shimon Reif

Nicola Maggio

Provided herein are method and kits for identifying thrombus origin based on temporal thrombin activity assay, and use thereof for optimizing post-ischemic event treatment, and further preventing recurrence of secondary ischemic events.

Methods and kits for identifying thrombus origin and optimizing post-ischemic event treatment

An isolated peptide of up to 6 amino acids comprising an amino acid sequence which inhibits binding of an endothelial cell protein C receptor (EPCR) ligand to the EPCR is disclosed. Also disclosed is an isolated peptide comprising an amino acid sequence which inhibits binding of an endothelial cell protein C receptor (EPCR) ligand to the EPCR, wherein the peptide comprises a modification in at least one amino acid. Also disclosed is a molecule comprising an amino acid sequence which inhibits binding of an endothelial cell protein C receptor (EPCR) ligand to the EPCR attached to a heterologous moiety. Pharmaceutical compositions and methods of treatment are also disclosed.

Peptides that inhibit binding of EPCR to its ligand to treat inflammation

Compositions and methods for treating malignant gliomas such as glioblastoma are provided, comprising a combination of a peptide conjugate comprising an amino acid sequence derived from the N-terminus of the receptor PAR-1, and the chemotherapeutic agent temozolomide.

Compositions and methods for treating glioblastoma

The present invention is directed to a peptide conjugate comprising an alpha-amino protecting moiety, a peptide comprising the amino acid sequence at least 3 amino-acid long derived from the C'-terminus of PAR-1, or an active variant thereof and a protease-disabling moiety. The present invention is further directed to pharmaceutical compositions comprising the peptide conjugate and use thereof for treating diseases and disorder associated with excessive PAR-1 activity.

PAR-1 based therapeutic conjugates and uses thereof

Disclosed is a method for inhibiting Ras-induced or mediated proliferation of cells associated with a non-malignant disease, disorder or pathological condition. The method entails administering to a patient a Ras antagonist in an amount effective to inhibit the proliferation. The invention is particularly applicable to diseases characterized by a proliferation of T-cells such as autoimmune disease, e.g., type 1 diabetes, lupus and multiple sclerosis, and pathological states such as graft rejection induced by the presentation of a foreign antigen such as a graft in response to a disease condition (e.g., kidney failure). Other non-malignant diseases characterized by proliferations of cells include cirrhosis of the liver and restenosis. Preferred Ras antagonists are S-trans-trans farnesylthiosalicylic acid (FTS) and structurally related compounds (or analogs) thereof.

Growing community of inventors

Kiryat Ono, Israel

Joab Chapman